Valera seeks acquisition, licensing opportunities for prostate cancer drug

By Elaine Rigoli

Tampa, Fla., Sept. 27 - Valera Pharmaceuticals, Inc. has established a number of equity funds in Europe and expects to see pan-Asian filings within the year for its implantable prostate cancer drug Vantas, David Tierney, president and chief executive officer, said during the UBS Global Life Sciences Conference in New York.

In addition to looking at a low-risk development strategy, Valera is looking for selective acquisition opportunities and exploring out-licensing options.

Located in Cranbury, N.J., Valera Pharmaceuticals is a specialty pharmaceutical company engaged in the development of products to treat urology and endocrinology diseases and disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.